New York, Jan 16, 2026, 20:14 EST — Market closed
- AbbVie dropped 1.1% on Friday, closing at $214.35, before inching up slightly in late after-hours trading.
- AbbVie and its partner Genmab released mixed results from their Phase 3 trial of epcoritamab in aggressive lymphoma.
- U.S. markets reopen Tuesday following Monday’s holiday; AbbVie is set to report earnings on Feb. 4.
AbbVie shares slipped 1.1% to close at $214.35 on Friday following mixed late-stage results for its lymphoma treatment, epcoritamab. In after-hours trading, the stock was last seen near $214.66, as U.S. indexes showed little movement. (Investing)
The readout arrives at a tough time for bulls. AbbVie is hustling to keep its growth story alive amid growing investor scrutiny of its oncology pipeline, with epcoritamab standing out as a key focus. Reuters reported that the Phase 3 trial missed its main goal, failing to deliver a statistically significant boost in overall survival, despite gains in other areas. (Reuters)
Friday’s close included a technical twist that could muddy the tape: AbbVie’s next quarterly dividend record date landed on Jan. 16. The company announced a raise to $1.73 per share, payable Feb. 17. Typically, the share price adjusts around this date since buyers afterward won’t collect the dividend. U.S. markets will be closed Monday for Martin Luther King Jr. Day, so the next full trading session to digest this info is Tuesday. (AbbVie News Center)
AbbVie reported that its EPCORE DLBCL-1 trial showed a progression-free survival benefit, with a hazard ratio of 0.74, indicating patients lived longer without disease progression. However, overall survival fell short of statistical significance, clocking in at an HR of 0.96. The study enrolled 483 patients and compared epcoritamab to investigator’s choice of chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma. (AbbVie News Center)
Genmab CEO Jan van de Winkel described the results as “the first Phase 3 study evaluating a bispecific antibody monotherapy to demonstrate improvements in progression-free survival.” He added that the partners remain “deeply committed to advancing the development of epcoritamab.” (Businessinsider)
Investors will be parsing what “mixed” actually signifies. In cancer trials, overall survival is a concrete endpoint — tracking how long patients live — and it often carries weight with doctors, payers, and regulators that a mere delay in disease progression might lack.
A risk paragraph stands out as well. Should subsequent studies fail to show a stronger survival benefit, AbbVie may struggle to make a compelling commercial case in the competitive blood-cancer arena. In that scenario, the stock might stay tied to incremental trial updates instead of reacting to wider sector trends.
The next major event is approaching faster than many expect. AbbVie plans to release its full-year and fourth-quarter 2025 earnings on Feb. 4, before markets open. The company will also hold a webcast at 8 a.m. Central time. (AbbVie News Center)
